Can an Indian Insurer Reject a Claim Citing Lack of FDA Approval? Here’s What the Law Says

One of my clients recently had a case which I am explaining below and if you are stuck in such similar situation, here is what to do.

Note: Due to attorney-client privilege, I cannot disclose complete case details or identify the actual parties involved. However, I am sharing the essential facts and legal approach so that if you find yourself in a similar situation, you can understand the available solutions and legal remedies.

TL;DR: An Indian insurer cannot legally reject a claim for cancer treatment simply because the medicine is not FDA (US) approved. Indian regulatory approvals — from the DCGI or CDSCO — are sufficient grounds for coverage. Such rejection orders are often arbitrary and can be challenged before the Insurance Ombudsman, IRDAI, or a Consumer Forum. You are not being scammed; you are being wrongfully denied.

Mrs. Geeta Sharma, a 54-year-old homemaker from Indore, was diagnosed with stage-three ovarian cancer in early 2024. Her treating oncologist at a reputed hospital in Nagpur prescribed a targeted therapy drug — a medicine that had full approval from the Drug Controller General of India (DCGI) and was widely used in Indian oncology protocols.

But when Mrs. Sharma's family submitted the claim to their insurer — a well-known public sector company — the TPA (Third Party Administrator) rejected it. The reason? The specific drug was not approved by the US Food and Drug Administration (FDA). Yes. You read that right.

The Sharmas were devastated. They had paid premiums for years. Now, with mounting hospital bills, the insurer was hiding behind a foreign regulatory standard. They first approached a local agent, then tried the insurance company's grievance cell. Nothing worked. That's when they reached the Chamber of Advocate Sudhir Rao.

Advocate Sudhir Rao and his office immediately identified the core issue: the insurance policy's terms did not require FDA approval. The rejection was based on an internal guideline, not the policy wording. And here's the thing — Indian insurance law, including the IRDAI (Health Insurance) Regulations, requires claims to be adjudicated based on Indian regulatory standards. Period.

The office argued before the Insurance Ombudsman that the medicine was DCGI-approved, clinically necessary, and within the scope of the policy. They submitted expert opinions, the hospital's treatment protocol, and the drug's CDSCO approval letter. The Ombudsman agreed. The claim was honoured within weeks. Advocate Sudhir Rao's specialised knowledge of health insurance regulations and regulatory compliance was critical in securing that outcome for the client.

Key Facts of the Case

• Mrs. Geeta Sharma held a comprehensive health insurance policy from a public sector insurer since 2018.
• The prescribed cancer drug had full approval from the Drug Controller General of India (DCGI).
• The TPA rejected the claim citing "lack of US FDA approval" — a condition never mentioned in the policy document.
• The insurance company's own grievance cell upheld the rejection without any independent medical review.
• No policy clause empowered the insurer to mandate US FDA clearance for Indian treatments.
• The claim was covered under the policy's "hospitalisation and medical treatment" section.
• The Insurance Ombudsman ruled in favour of the insured, ordering full payment with interest.
• IRDAI regulations prohibit insurers from applying arbitrary criteria beyond the policy terms.

The Direct Legal Answer

No. An Indian insurer cannot reject a claim citing lack of US FDA approval. That's not how the law works.

Why would an insurer mention FDA approval at all?

Some insurance companies, particularly their TPAs, try to impose internal guidelines that go beyond the policy's actual wording. They might argue that the drug is "experimental" or "not proven effective" because the FDA hasn't approved it. But Indian law recognises approvals from the DCGI and CDSCO as fully valid. If a medicine is approved for use in India by the appropriate regulatory authority, it's legally treatment, not experimental.

Does the policy wording matter?

Absolutely. Read the policy document carefully. Does it explicitly say "only FDA-approved drugs are covered"? Most standard policies do not contain such a clause. If the policy is silent on this, the insurer cannot read in a requirement that isn't there. The Insurance Ombudsman and Consumer Forums consistently rule against such creative rejections.

Advice in Such Cases

Consult with Lawyer: The very basic and important step to start is talk to Lawyer / advocate. You should not hesitate in paying his consultation fee i.e. might be in range of Rs. 10,000 to 50,000 depends case to case. He is helping you in this situation to come out. He is expert in the domain and can help you explain the procedure which you might have never explored. A good lawyer can get the issues resolved much faster than you think.

Also file a complaint with IRDAI's Grievance Cell at the earliest. They can intervene directly with the insurer. Keep every document — the rejection letter, the policy, medical reports, and the prescription. And don't accept the first rejection as final. Many insurers reject claims initially hoping you'll give up. That's not a legal strategy; it's a business practice. You can push back.

Make no mistake — this type of matter requires an advocate who regularly handles health insurance and consumer disputes. The procedural nuances — from filing before the Ombudsman to challenging arbitrary rejection grounds — are well understood by specialists. A general practitioner may miss the regulatory arguments that win these cases.

Applicable Sections of Law

• IRDAI (Health Insurance) Regulations, 2016: Prohibits unreasonable claim rejection and mandates that policy terms alone govern claim decisions.
• Consumer Protection Act, 2019: An insurance company refusing a legitimate claim commits an "unfair trade practice" under Section 2(47) read with Section 10 of the Act.
• Indian Contract Act, 1872 — Section 23: Any condition in a contract that is against public policy (e.g., requiring FDA approval for Indian treatment) is void.
• Drugs and Cosmetics Act, 1940: Recognises DCGI/CDSCO approvals as sufficient for use of drugs in India — foreign approvals are not mandatory.

Jurisdiction — Where to File the Case

For such matters, you have three main options. First, the Insurance Ombudsman — your policy's governing office will have territorial jurisdiction based on where you live or where the policy was issued. Second, the Consumer Disputes Redressal Forum (District/State/National) depending on the claim amount. Third, you can approach IRDAI's Grievance Cell directly for regulatory intervention. Jurisdiction matters because each forum has different procedures and timelines. Filing in the wrong forum can delay your case by months.

How Courts Typically Approach Such Cases

Indian courts and consumer forums take a dim view of arbitrary claim rejections. The consistent principle is that insurance policies are contracts of utmost good faith (uberrima fides). Courts frequently invoke the contra proferentem rule — any ambiguity in the policy wording is interpreted in favour of the insured. So if the policy is silent on FDA approval, the court will not allow the insurer to invent that requirement. The burden is on the insurer to prove the claim is excluded — not on you to prove it's covered. Some courts have also awarded compensation for mental harassment and punitive damages in such cases.

If You Are the Victim

• Do not accept the rejection silently. Insist on a written, detailed reason from the insurer.
• Gather all your medical documents, especially the drug's DCGI/CDSCO approval certificate.
• File a complaint with the Insurance Ombudsman within one year of the rejection.
• Simultaneously approach IRDAI via their online portal.
• If needed, file a consumer complaint at the appropriate Consumer Forum.

Documents You Must Keep Ready

• Original health insurance policy document and renewal receipts
• Claim rejection letter from the TPA or insurer (with date and reference)
• All medical reports, prescription, and hospital bills
• DCGI/CDSCO approval letter for the prescribed drug (obtain from hospital or manufacturer)
• Any correspondence with the insurance company
• Identity proof (Aadhaar, PAN)
• Copy of the treatment protocol and doctor's notes

What Evidence Is Required?

• Policy document (to prove no FDA requirement exists)
• Rejection letter (to establish the stated reason)
• Medical prescription and hospital records (to prove the drug was necessary)
• DCGI/CDSCO approval (primary evidence that the drug is legally approved in India)
• IRDAI's circulars/guidelines (to show the regulator's position on foreign approvals)
• Any expert medical opinion confirming the drug's efficacy and standard use in India
• Secondary: journal articles, treatment guidelines from Indian oncology bodies

Timeline of Legal Process

• Step 1 — Internal Grievance: 15-30 days. File with the insurer's grievance cell.
• Step 2 — IRDAI Complaint: 30-45 days for a regulatory response.
• Step 3 — Insurance Ombudsman: 3-6 months from filing to award. Hearing within 45 days.
• Step 4 — Consumer Forum: 6 months to 2 years depending on the forum level and case complexity.
• Step 5 — Appeal (if any): Can add another 6-12 months. Most cases resolve at the Ombudsman level.

Understanding the Costs

The total cost of a matter like this varies significantly from one case to the next — it depends on the complexity of the dispute, the forum involved, the number of hearings, and the specific facts of your situation. There is no single fixed figure that applies to everyone.

A professional advocate can give you an accurate estimate only after reviewing all your facts and documents in a consultation.

Can the Matter Be Settled Out of Court?

Yes. In fact, most insurance claim disputes are settled before formal adjudication. The Insurance Ombudsman often facilitates a conciliation process. IRDAI also encourages settlement through its grievance mechanism. If the insurer realises their position is legally weak — and it often is in FDA-approval cases — they may offer to settle. You can also approach a Lok Adalat for a binding settlement under the Legal Services Authorities Act. But be careful: don't accept a lowball settlement without legal advice. The insurance company's initial offer might be much less than what you're entitled to under the policy.

Common Mistakes People Make

• Engaging an advocate without domain experience: This type of case requires knowledge of insurance regulations, medical evidence, and consumer law. A general practitioner may miss the critical regulatory argument that wins the case.
• Accepting the first rejection as final: Many insurers reject claims as a first response. They count on you giving up. Don't.
• Not reading the policy document carefully: If the policy doesn't mention FDA approval, you already have your strongest argument.
• Failing to document everything: Every call, email, and letter should be recorded. Dates matter.
• Posting about the case on social media: This can complicate things. Keep your case confidential until it's resolved.
• Signing a settlement without understanding your rights: Never sign a full and final discharge unless you're certain it covers all your dues.

FAQs People Normally Have

Can the insurer ask for FDA approval if the policy is silent?

No. If the policy doesn't mention FDA approval, the insurer cannot impose it as a condition. The policy document governs the contract, not internal guidelines.

What if the drug is approved in India but not commonly used?

That's a clinical decision, not an insurance one. If the treating doctor prescribes it and it's DCGI-approved, the insurer generally must cover it unless the policy explicitly excludes "experimental treatments."

How fast can this be resolved?

Through the Insurance Ombudsman, many cases are resolved within 3-6 months. Consumer forums take longer.

Can I claim compensation for the delay?

Yes. Consumer forums and the Ombudsman can award interest (often 9-12% per annum) on delayed claims, plus compensation for mental harassment.

Should I file a consumer case directly?

Not necessarily. The Ombudsman process is faster and free. Use the consumer forum as a second resort if the Ombudsman route fails or the amount is very high.

This article is general legal information, not legal advice. Consult a qualified advocate about your specific situation.

Advocate Sudhir Rao, Supreme Court of India